References
- Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med. 2006; 119(Suppl. 1)S3–S9
- Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365: 1333–1346
- Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005; 4: 6
- Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66: 51–83
- Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006; 119(Suppl. 1)S24–S30
- Cohen AM, Rosenmann E, Rosenthal T. The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings. Am J Hypertens. 1993; 6: 989–995
- Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing property. Med Hypotheses 2005; 64: 476–478
- Doggrell SA. Telmisartan—killing two birds with one stone. Expert Opin Pharmacother. 2004; 5: 2397–2400
- Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27: 1015
- Michel MC, Bohner H, Koster J. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Safety 2004; 27: 335–344
- Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005; 28: 498
- Rodgers PT, Fuke DC. New and emerging strategies for reducing cardiometabolic risk factors. Pharmacotherapy 2006; 26: 13S–31S
- Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 2004; 43: 993–1002
- Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005; 42(Suppl. 1)S9–S16
- Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, et al. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004; 576: 492–497
- Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054–2057
- Farley S. Metabolic syndrome: Two for the price of one. Nature Reviews Drug Discovery 2004; 3: 475
- Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 8: 884–890
- Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005; 46: 137–143
- Israeli ZH. Clinical pharmacokinetics of angiotension II (AT1) receptor blockers in hypertension. J Human Hypertens. 2000; 14(Suppl 1)